Viva Star Bioscience
Viva Star Bio is advancing proprietary and differentiated assets (LPAR1 antagonist and NLRP3 inhibitors) for the treatment of respiratory disorders such as pulmonary fibrosis, asthma, etc.
)
January 11-14, 2027 | San Francisco Marriott Marquis
January 15, 2027 | Virtual
January 11-14, 2027 | San Francisco
January 15, 2027 | Virtual
)
)
January 11-14, 2027 | San Francisco Marriott Marquis
January 15, 2027 | Virtual
January 15, 2027 | Virtual
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)